A New Label-Free Screen for Steroid 5α-Reductase Inhibitors Using LC-MS

    October 2016 in “ Steroids
    Jukkarin Srivilai, Karma Rabgay, Nantaka Khorana, Neti Waranuch, Nitra Nuengchamnong, Kornkanok Ingkaninan
    Image of study
    TLDR Researchers developed a new method to find substances in herbs that can block a specific enzyme linked to hair loss.
    In 2016, researchers developed a label-free liquid chromatography-mass spectrometry (LC-MS) assay to identify inhibitors of steroid 5α-reductase (S5aR), an enzyme linked to conditions like androgenic alopecia. The assay was optimized and validated, showing high reproducibility with a Z' factor of 0.77. It was applied to screen 11 Thai herbal extracts, with Impatiens balsamina L. and Curcuma longa L. demonstrating significant S5aR inhibitory activity, with IC50 values of 5.4±0.2 µg/mL and 9.0±1.2 µg/mL, respectively. The study concluded that the assay is suitable for medium throughput screening and could be used in small laboratory settings to identify potential anti-androgenic compounds in herbal extracts.
    Discuss this study in the Community →

    Research cited in this study

    11 / 11 results

    Related Community Posts Join

    6 / 493 results

      community Detailed 6 months update for FUE HT and 4 years of FIN-MIN journey

      in Progress Pictures  192 upvotes 1 year ago
      A 25-year-old who has been using minoxidil and finasteride for 4 years to treat hair loss, underwent a successful FUE hair transplant in Mumbai, India, in April 2023. The user reported positive results, including increased hair density and reduced frizziness, and plans to continue treatment for further growth.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 3 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Related Research

    4 / 4 results